Aspen Pharmacare

From Wikipedia, the free encyclopedia
  (Redirected from Aspen Pharma)
Jump to: navigation, search
Aspen Pharmacare Holdings Limited
Public (JSE: APN)
JSE Limited
Industry Health care, pharmaceuticals
Founded 1850,[1] public 1997
Headquarters Durban, South Africa[2]
Key people
Stephen Saad (Group Chief Executive)
Products Pharmaceuticals and health care
Revenue IncreaseR12.4 billion (FY 2011)[1]
Profit IncreaseR5.6 billion (FY 2011)[1]
Total assets IncreaseR26.8 billion (FY 2011)[1]
Total equity IncreaseR13.3 billion (FY 2011)[1]
Owner Stephen Saad
Number of employees

Aspen Pharmacare Holdings Limited is a multinational South African holding company for pharmaceutical concerns[3] and the largest drug company in Africa.[4][5]


Activity in HIV/AIDS-related medicines[edit]

After complaints of anticompetitive activities by Boehringer Ingelheim and GlaxoSmithKline in 2003, Aspen was granted licenses from the companies to create generic versions of antiretrovirals (ARV) for use in the Sub-Saharan portion of Africa.[6] At the time, Aspen was already the largest generic medicine distributor in South Africa.[6] Subsequent inspections by international organizations led to a rapid increase in distribution capabilities, primarily though integration with alliance partners.[6] The company's efforts led to expanded access to affordable treatments for HIV/AIDS.[7]


The company supplies more than 650 branded medicines, specializing in generics and treatments for HIV/AIDS and tuberculosis.[5]


  1. ^ a b c d e f "Aspen Pharmacare Holdings Limited Annual Report 2011". Aspen Holdings. Retrieved 30 June 2012. 
  2. ^ ASPEN Corporate Office Durban, retrieved 1 July 2012
  3. ^ APN Profile & Executives - Aspen Pharmacare Holdings Ltd - Bloomberg
  4. ^ Aspen Pharmacare Offers to Buy Australia's Sigma Pharma for $1.23 Billion - Bloomberg
  5. ^ a b Ricardo Meléndez-Ortiz; Pedro Roffe (1 January 2009). Intellectual Property and Sustainable Development: Development Agendas in a Changing World. Edward Elgar Publishing. pp. 178–. ISBN 978-1-84844-645-8. Retrieved 30 June 2012. 
  6. ^ a b c Patrick Lumumba Osewe; Yvonne Korkoi Nkrumah; Emmanuel K. Sackey (15 June 2008). Improving Access to HIV/AIDS Medicines in Africa: Trade-Related Aspects of Intellectual Property Rights (TRIPS) Flexibilities Utilization. World Bank Publications. pp. 35–39. ISBN 978-0-8213-7544-0. Retrieved 30 June 2012. 
  7. ^ Céline Louche; Samuel O. Idowu; Walter Leal Filho (30 April 2010). Innovative Csr: From Risk Management to Value Creation. Greenleaf Publishing. pp. 158–. ISBN 978-1-906093-35-8. Retrieved 30 June 2012.